Until that completes and regulators review it, retatrutide remains investigational, with no marketing authorization, no licensed supply, and no approved labeling defining who it is for or how it should be used
In particular: NICE Technology Appraisal TA875 provides a positive recommendation for semaglutide (Wegovy) for chronic weight management in adults meeting specific criteria (BMI 35 kg/m with at least one weight-related comorbidity, or BMI 3034.9 kg/m in certain circumstances), when used within a specialist weight management service
Wegovy comes as a sterile solution, but removing the cap can introduce germs, which may increase the risk of infection
All of the known GLPs produce clinically significant reductions in hemoglobin A1c levels
Your coach will guide the progression
Comprehensive Weight Management